KURA News and Press, Kura Oncology Inc. From 06/18/19

SAN DIEGO, June 18, 2019 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company focused on the development of precision medicines for oncology, today announced that it has commenced an underwritten public offering, subject to market and other cond...

Kura Oncology (NASDAQ: KURA ) +7.9% pre-market after announcing data from a phase 2 clinical trial of its tipifarnib drug candidate in patients with relapsed or refractory peripheral T-cell lymphoma. More news on: Kura Oncology, Inc., Healthcare stocks news, Stocks on the move, Rea...

– Primary endpoint achieved with 45% and 42% ORR in AITL and CXCL12+ AITL/PTCL-NOS expansion cohorts – – PTCL patients with tumors characterized by high CXCL12/CXCR4 expression ratio experienced an ORR of 47% and a clinical benefit rate of 82% – – 50% ...

The following slide deck was published by Kura Oncology, Inc. in conjunction with this Read more ...

SAN DIEGO, May 08, 2019 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company focused on the development of precision medicines for oncology, today announced that Troy Wilson, Ph.D., J.D., President and Chief Executive Officer, is scheduled to pr...

Kura Oncology, Inc. (KURA) Q1 2019 Earnings Conference Call May 07, 2019 04:30 PM ET Executives Pete De Spain - VP of IR Troy Wilson - President, CEO Antonio Gualberto - CMO, Head of development Marc Grasso - CFO, CBO Analysts Jonathan Chang - STB Leerink Chris Shibutan...

Kura Oncology (NASDAQ: KURA ): Q1 GAAP EPS of -$0.37 beats by $0.08 . Cash and equivalents of $165.5M. Press Release More news on: Kura Oncology, Inc., Earnings news and commentary, Healthcare stocks news,

– Registration-directed trial of tipifarnib in HRAS mutant HNSCC continues on track – – Data from ongoing Phase 2 trial of tipifarnib in CXCL12-driven PTCL accepted for oral presentations at EHA and ICML next month – – Data from ongoing Phase 2 trial ...

SAN DIEGO, April 30, 2019 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company focused on the development of precision medicines for oncology, today announced that it will report first quarter 2019 financial results after the close of U.S. finan...

Kura Oncology ( KURA +1.3% ) is up on below-average volume following the presentation of new data supporting the mechanism of action of lead drug tipifarnib at AACR in Atlanta. More news on: Kura Oncology, Inc., Healthcare stocks news, Stocks on the move, Read more ...